Cybin D/B/A Helus Pharma
HELP
11.46 EUR
1 day: -2.86% (-0.33 EUR)
The alert is saved directly without jumping back to the homepage.
Price alerts for HELP
Please log in to view and save price alerts.
Finanzen
Company info
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Aktuelle News
-
Cybin (HELP) Gets A Fresh Look On Trial Progress And CEO Change
Vorschau anzeigen
Why Cybin Stock Is Back on Investors’ Radar Cybin (HELP) has attracted fresh attention after progress in its psychedelic medicine pipeline, including HLP003 advancing into a Phase 3 trial for major depressive disorder, and the appointment of Michael Halstead as CEO. Cybin’s share price has moved sharply in recent months, with a 1 month share price return of 83.53% and a 90 day share price return of 215.69%. The 1 year total shareholder return of 87.72% contrasts with a weaker 5 year total...
-
Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions
Vorschau anzeigen
Cybin’s fair value estimate has moved from US$37.57 to US$41.62 per share, an adjustment of about 11% in the latest analyst model. Recent sector research on psychedelic neuropsychiatry stocks, along with updates around peers’ late stage programs and regulatory tone, is helping shape how analysts frame this higher fair value range for Cybin. Read on to see how these shifting assumptions and new data points can help you track the evolving narrative around the stock. Stay updated as the Fair...
-
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
Vorschau anzeigen
Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.
-
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
Vorschau anzeigen
Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and commercialization Ms. Donohue is the former Chief Human Resources Officer of Intra-Cellular, where she led the company’s people strategy and human resources infrastructure as it transitioned from a clinical to a commercial stage organization of 1,000+ employees Dr. Durgam is a recognized CNS drug-d
-
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Vorschau anzeigen
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 - - Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD - - Continued enrol